Thanks Ma420. Its a great interview, and AT expands on the additional pre-clinical work that looks at other indications beyond prostate cancer.
Clearly Clarity is developing a substantial platform that into the future will be huge. I can see the Company, if it were to survive as a separate entity, to be a leader in cancer diagnostics and therapy over a broader spectrum than the current market can possibly value.
It really is an exciting pioneer in the radiopharma space and AT is an impressive leader.
CU6 - Media and Industry News, page-566
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$8.66 |
Change
-0.045(0.52%) |
Mkt cap ! $2.756B | |||
| Open | High | Low | Value | Volume |
| $8.65 | $8.79 | $8.50 | $4.786M | 555.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 3714 | $8.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $8.66 | 23 | 1 |
View Market Depth
| Last trade - 12.50pm 27/09/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |